NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a company with a patient centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive better outcomes, streamline care, and elevate the patient experience, today announced that its common stock, par value $0.001 per share (the "Common Stock"), will begin trading on a split-adjusted basis on The Nasdaq Capital Market at the opening of trading today, following the effectiveness of a previously announced 1-for-20 reverse stock split of the Company’s issued and outstanding Common Stock (the "Reverse Stock Split"). The Common Stock will continue to trade on The Nasdaq Capital Market under the symbol "NXGL" and has been assigned a new CUSIP number, 65344E 206.